Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer

  • Larissa Nekhlyudov
  • Lingling Li
  • Dennis Ross-Degnan
  • Anita K. Wagner
Brief Report


Adjuvant hormonal therapy (HT) for breast cancer improves survival, yet studies have shown that early discontinuation and suboptimal adherence are common. We aimed to expand existing literature by describing patterns of HT use, specifically focusing on the prevalence and predictors of treatment interruptions of varying durations. We identified 2,207 women who were diagnosed with early-stage breast cancer and who initiated adjuvant HT between July 1, 2000 and 2005, and were followed through August 1, 2006, at a New England health plan. Of 58% of women who initiated HT within 12 months after diagnosis, 769 (54.6%) used tamoxifen, 354 (25.1%) used an aromatase inhibitor, and 285 (20.3%) switched between the two agents during the follow-up period. By the end of the first year of treatment, 79% of women remained on therapy without gaps exceeding 60 days and 85% without gaps exceeding 180 days. By year 5, only 27 and 29% remained without 60- and 180-day gaps, respectively. Results from extended Cox proportional hazards regression models indicated that only age ≥70 years (vs. less than 50 years) was consistently associated with an increased likelihood of treatment gaps, with hazard ratio (HR) of 2.00 [95% CI 1.36–2.94] for gaps of ≥60 days, HR 2.09 [1.38–3.16] for gaps of ≥90 days, and HR 2.14 [1.36–3.37] for gaps of ≥180 days in the first follow-up year, with similar results in subsequent years. Longer gaps were associated with a lower likelihood of resuming therapy. In summary, interruptions in HT therapy began in the first year after initiating treatment and continued through subsequent years and were common among insured women, particularly the elderly. Clinicians caring for breast cancer survivors should explicitly ask women about their medication use, explore barriers to adherence, and encourage them to continue long-term therapy as advised by treatment guidelines.


Breast cancer Adherence Adjuvant hormonal therapy 


  1. 1.
    Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish breast cancer cooperative group. J Natl Cancer Inst 88:1543–1549 (1996)Google Scholar
  2. 2.
    Baum M, Buzdar AU, Cuzick J, Forbes J, Houghton J, Klijn JGM et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. The Lancet 359(9324):2131–2139CrossRefGoogle Scholar
  3. 3.
    Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509–518PubMedCrossRefGoogle Scholar
  4. 4.
    Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629Google Scholar
  5. 5.
    Aiello EJ, Buist DS, Wagner EH, Tuzzio L, Greene SM, Lamerato LE et al (2008) Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat 107:397–403Google Scholar
  6. 6.
    Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602–606PubMedCrossRefGoogle Scholar
  7. 7.
    Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Research Treat 99:215–220CrossRefGoogle Scholar
  8. 8.
    Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322–328PubMedGoogle Scholar
  9. 9.
    Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309–3315PubMedCrossRefGoogle Scholar
  10. 10.
    Owusu C, Buist DSM, Field TS, Lash TL, Thwin SS, Geiger AM et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-breast cancer. J Clin Oncol 26:549–555PubMedCrossRefGoogle Scholar
  11. 11.
    Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556–562PubMedCrossRefGoogle Scholar
  12. 12.
    Ziller V, Kalder M, Albert US, Holzhauer W, Miller M, Wagner U et al (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20:401–402Google Scholar
  13. 13.
    Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27:3445–3451PubMedCrossRefGoogle Scholar
  14. 14.
    Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128PubMedCrossRefGoogle Scholar
  15. 15.
    Sedjo RL, Devine S (2010) Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125:191–200PubMedCrossRefGoogle Scholar
  16. 16.
    Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45:431–439PubMedCrossRefGoogle Scholar
  17. 17.
    Barron TI, Connolly R, Bennett K, Freely J, Kennedy J (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109:832–839PubMedCrossRefGoogle Scholar
  18. 18.
    Nattinger AB, Laud PW, Bajorunaite R, Sparapani RA, Freeman JL (2004) An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res 39(6 Pt 1):1733–1749PubMedCrossRefGoogle Scholar
  19. 19.
    Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN et al (2002) Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40(Supplement):IV55–IV61Google Scholar
  20. 20.
    Schneeweiss S, Wang PS, Avorn J, Maclure M, Levin R, Glynn RJ (2004) Consistency of performance ranking of comorbidity adjustment scores in Canadian and US utilization data. J Gen Intern Med 19:444–450PubMedCrossRefGoogle Scholar
  21. 21.
    Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71:1–9PubMedGoogle Scholar
  22. 22.
    Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56–66PubMedCrossRefGoogle Scholar
  23. 23.
    Pezzin LE, O’Niel MB, Nattinger AB (2009) The economic consequences of breast cancer adjuvant hormonal treatments. J Gen Intern Med 24(Suppl 2):S446–S450PubMedCrossRefGoogle Scholar
  24. 24.
    Neugut AI, Subar M, Ty Wilde E, Stratton S, Brouse CH, Hillyer GC et al (2011) Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534–2542PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Larissa Nekhlyudov
    • 1
    • 2
  • Lingling Li
    • 1
  • Dennis Ross-Degnan
    • 1
  • Anita K. Wagner
    • 1
  1. 1.Department of Population MedicineHarvard Medical School/Harvard Pilgrim Health Care InstituteBostonUSA
  2. 2.Division of MedicineHarvard Vanguard Medical AssociatesBostonUSA

Personalised recommendations